Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to determine the efficacy and safety in treating patients with chronic central serous chorioretinopathy with the drug eplerenone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tel-Aviv Sourasky Medical Center
• Treatments: Eplerenone; Spironolactone

Criteria

Inclusion Criteria:

• Chronic central serous chorioretinopathy (CSCR): Previous diagnosis of CSCR, persistent subretinal fluid on OCT for more than 4 months after initial presentation to the eye clinic

Exclusion Criteria:

• Other retinal disease

• Choroidal neovascularization

• Diabetes

• A history of uveitis

• Ocular surgery in the prior 3 months

• Allergy to fluorescein or indocyanine green

• Pregnancy, lactation or female patients in fertility age not treated with contraceptive pills

• Creatinine clearance < 50 ml/min

• Hyperkalemia > 5 mmol/l

• Patients treated with drugs deactivated by cytochrome P450 3A4 (CYP3A4)

• Serum creatinine > 2 mg/dl in men or > 1.8 mg/dl in women

• Treatment with potassium sparing agents or potassium

• Treatment with Angiotensin converting enzyme (ACE)/angiotensin II receptor blocker (ARB) inhibitors